BRISTOL-MYERS Squibb has announced that Opdivo (nivolumab) will be listed on the Pharmaceutical Benefits Scheme (PBS) from 1st August for locally advanced or metastatic non-small cell lung cancer (NSCLC) and advanced (stage IV) clear cell variant renal cell carcinoma (RCC).
Certain conditions apply to the listings of this expensive therapy.
In Australia, lung cancer is the leading cause of cancer deaths claiming 8,000 victims each year, while 3,500 new cases of kidney cancer are diagnosed every year.
CLICK HERE for the Opdivo PI.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Aug 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Aug 17